The Role of Salivary Biomarkers in the Early Detection and Prognosis of Oral Squamous Cell Carcinoma

Background: Oral squamous cell carcinoma (OSCC) is a prevalent and aggressive form of cancer with a high-mortality rate. Early detection and prognosis are critical for improving patient outcomes. Salivary biomarkers have emerged as noninvasive and promising tools for the early detection and monitoring of OSCC. This study aims to evaluate the role of specific salivary biomarkers in the early detection and prognosis of OSCC. Materials and Methods: A total of 100 participants were recruited for this study, including 50 patients diagnosed with OSCC and 50 healthy controls. Saliva samples were collected from all the participants and analyzed for the presence and concentration of specific biomarkers, including cytokines, DNA methylation patterns, and microRNAs. Enzyme-linked immunosorbent assay, polymerase chain reaction, and next-generation sequencing were employed to quantify and identify the biomarkers. Results: The study found that the levels of specific salivary biomarkers, such as interleukin-6 (IL-6), microRNA-21 (miRNA-21), and hypermethylation of the p16 gene, were significantly elevated in OSCC patients compared to healthy controls. The mean concentration of IL-6 in OSCC patients was 45.3 pg/mL, whereas in healthy controls, it was 12.7 pg/mL. Similarly, miR-21 levels were 3.5-fold higher and p16 hypermethylation was observed in 70% of OSCC patients compared to 10% in the control group. The sensitivity and specificity of these biomarkers for OSCC detection were 85% and 90%, respectively. Conclusion: Salivary biomarkers such as IL-6, miR-21, and p16 hypermethylation demonstrate significant potential in the early detection and prognosis of OSCC. These noninvasive biomarkers can aid in the timely diagnosis and management of OSCC, improving patient outcomes and survival rates. Further large-scale studies are warranted to validate these findings and integrate salivary biomarker testing into routine clinical practice.